COST-EFFECTIVENESS OF SCREENING AND TREATMENT OF ALZHEIMER'S DISEASE WITH DONEPEZIL IN THE UNITED KINGDOM

被引：0
|
作者：
Getsios, D. [1 ]
Blume, S. [2 ]
Ishak, K. J. [3 ]
MacLaine, G. [4 ]
机构：
[1] United BioSource Corp, Concord, MA USA
[2] United BioSource Corp, Bethesda, MD USA
[3] United BioSource Corp, Montreal, PQ, Canada
[4] Eisai Europe Ltd, Hatfield, Herts, England
来源：
VALUE IN HEALTH | 2009年 / 12卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A191 / A191
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
    Neumann, PJ
    Hermann, RC
    Kuntz, KM
    Araki, SS
    Duff, SB
    Leon, J
    Berenbaum, PA
    Goldman, PA
    Williams, LW
    Weinstein, MC
    NEUROLOGY, 1999, 52 (06) : 1138 - 1145
  • [2] Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
    Lopez-Bastida, Julio
    Hart, Warren
    Garcia-Perez, Lidia
    Linertova, Renata
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 16 (02) : 399 - 407
  • [3] COST-EFFECTIVENESS OF DONEPEZIL IN THE TREATMENT OF PATIENTS WITH ALZHEIMER'S DISEASE: AN UPDATE
    Chyr, L. C.
    Yapici, H. O.
    Padula, W., V
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [4] COST-EFFECTIVENESS OF DONEPEZIL IN ALZHEIMER'S DISEASE IN SWEDEN
    Mesterton, J.
    By, A.
    Sandelin, R.
    Jonsson, L.
    VALUE IN HEALTH, 2009, 12 (07) : A369 - A369
  • [5] COST-EFFECTIVENESS STUDY IN PATIENTS WITH MILD TO MODERATELY SEVERE ALZHEIMER'S DISEASE: PROJECTED BENEFITS OF DONEPEZIL IN THE UNITED KINGDOM
    Getsios, D.
    Blume, S.
    Ishak, K. J.
    MacLaine, G.
    VALUE IN HEALTH, 2009, 12 (03) : A191 - A191
  • [6] Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease
    Teipel, Stefan J.
    Ewers, Michael
    Reisig, Veronika
    Schweikert, Bernd
    Hampel, Harald
    Happich, Michael
    EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 2007, 257 (06) : 330 - 336
  • [7] Long-term cost-effectiveness of donepezil for the treatment of Alzheimer’s disease
    Stefan J. Teipel
    Michael Ewers
    Veronika Reisig
    Bernd Schweikert
    Harald Hampel
    Michael Happich
    European Archives of Psychiatry and Clinical Neuroscience, 2007, 257 : 330 - 336
  • [8] The cost-effectiveness of donepezil and rivastigmine in the treatment of Alzheimer's disease in Thailand private hospital
    Pattanaprateep, O
    Phongchareonsuk, P
    Chaikledkaew, U
    VALUE IN HEALTH, 2005, 8 (03) : 314 - 315
  • [9] COST-EFFECTIVENESS OF ADUCANUMAB VERSUS DONEPEZIL FOR PATIENTS WITH EARLY ALZHEIMER'S DISEASE
    Xiong, X.
    Li, M.
    Lu, Z. K.
    VALUE IN HEALTH, 2023, 26 (06) : S85 - S85
  • [10] The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease
    Loveman, E
    Green, C
    Kirby, J
    Takeda, A
    Picot, J
    Payne, E
    Clegg, A
    HEALTH TECHNOLOGY ASSESSMENT, 2006, 10 (01) : III - +
12345